Targeted gene therapy for the treatment of heart failure

Canadian Journal of Cardiology

Volumn 27, Issue 3, 2011, Pages 265-283

  Rapti, Kleopatra ^a   Chaanine, Antoine H ^a   Hajjar, Roger J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ADENOSINE; ADENOVIRUS VECTOR; ANTISENSE OLIGONUCLEOTIDE; BELATACEPT; CALCIUM; CALCIUM BINDING PROTEIN; CALCIUM CYCLING PROTEIN; COLLAGENASE; CYCLOSPORIN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GLYCERYL TRINITRATE; HEPARIN; HISTAMINE; HYALURONIDASE; LENTIVIRUS VECTOR; NAKED DNA; NITROPRUSSIDE SODIUM; PARVOVIRUS VECTOR; PLASMID DNA; PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR; SEROTONIN; SILDENAFIL; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; ADRENERGIC SYSTEM; ANGIOGENESIS; ANTIANGIOGENIC GENE THERAPY; ANTIGEN PRESENTING CELL; CARDIOVASCULAR DISEASE; CELL THERAPY; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; ENZYME INHIBITION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; HEART FAILURE; HEART MUSCLE; HEART MUSCLE CELL; HUMAN; IMMUNOGENICITY; LENTIVIRINAE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PLURIPOTENT STEM CELL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSGENIC ANIMAL; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT FAILURE; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT; VIRUS REPLICATION;

EID: 79960793567     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2011.02.005     Document Type: Review

References (294)

1. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:480-6.
2. Dixon JA, Spinale FG. Large animal models of heart failure: a critical link in the translation of basic science to clinical practice. Circ Heart Fail 2009;2:262-71.
3. Abate E, Sartor R, Ceconi C, et al. Pharmacological treatment of chronic systolic heart failure: are we scraping the bottom of the barrel? J Cardiovasc Med 2010;11:893-905.
4. Ramani GV, Uber PA, Mehra MR. Chronic heart failure: contemporary diagnosis and management. Mayo Clin Proc 2010;85:180-95.
5. Lamour JM, Kanter KR, Naftel DC, et al. The effect of age, diagnosis, and previous surgery in children and adults undergoing heart transplantation for congenital heart disease. J Am Coll Cardiol 2009;54:160-5.
6. Marelli D, Kobashigawa J, Hamilton MA, et al. Long-term outcomes of heart transplantation in older recipients. J Heart Lung Transplant 2008; 27:830-4.
7. HHS/HRSA/HSB/DOT; UNOS; Arbor Research Collaborative for Health. Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1994-2003. Available at: http://www.ustransplant.org/csr/current/nats.aspx. Accessed September 20, 2010.
8. Davis J, Westfall MV, Townsend D, et al. Designing heart performance by gene transfer. Physiol Rev 2008;88:1567-651.
9. Lyon AR, Sato M, Hajjar RJ, et al. Gene therapy: targeting the myocardium. Heart 2008;94:89-99.
10. Katz MG, Swain JD, White JD, et al. Cardiac gene therapy: optimization of gene delivery techniques in vivo. Hum Gene Ther 2010;21:371-80.
11. Chu G, Haghighi K, Kranias EG. From mouse to man: understanding heart failure through genetically altered mouse models. J Card Fail 2002; 8:S432-49.
12. Balakumar P, Singh AP, Singh M. Rodent models of heart failure. J Pharmacol Toxicol Methods 2007;56:1-10.
13. Lipskaia L, Chemaly ER, Hadri L, et al. Sarcoplasmic reticulum Ca(2+) ATPase as a therapeutic target for heart failure. Expert Opin Biol Ther 2010;10:29-41.
14. Rosenberg SA, Aebersold P, Cornetta K, et al. Gene transfer into humans- immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990;323:570-8.
15. Isner JM, Pieczek A, Schainfeld R, et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996;348:370-4.
16. Schumacher B, Pecher P, von Specht BU, et al. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 1998; 97:645-50.
17. Journal of Gene Medicine. Gene Therapy Clinical Trials Worldwide. Available at: http://www.wiley.com/legacy/wileychi/genmed/clinical/. Accessed October 5, 2010.
18. Gray SJ, Samulski RJ. Optimizing gene delivery vectors for the treatment of heart disease. Expert Opin Biol Ther 2008;8:911-22.
19. Conwell CC, Huang L. Recent Advances in Non-viral Gene Delivery. Adv Genet 2005;53PA:1-18.
20. Niidome T, Huang L. Gene therapy progress and prospects: nonviral vectors. Gene Ther 2002;9:1647-52.
21. Bigger BW, Tolmachov O, Collombet JM, et al. An araC-controlled bacterial cre expression system to produce DNA minicircle vectors for nuclear and mitochondrial gene therapy. J Biol Chem 2001;276: 23018-27.
22. Mayrhofer P, Schleef M, Jechlinger W. Use of minicircle plasmids for gene therapy. Methods Mol Biol 2009;542:87-104.
23. Kapsa R, Kornberg AJ, Byrne E. Novel therapies for Duchenne muscular dystrophy. Lancet Neurol 2003;2:299-310.
24. Freitas SS, Azzoni AR, Santos JA, et al. On the stability of plasmid DNA vectors during cell culture and purification. Mol Biotechnol 2007;36: 151-8.
25. Muller OJ, Leuchs B, Pleger ST, et al. Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors. Cardiovasc Res 2006;70:70-8.
26. Ruponen M, Honkakoski P, Ronkko S, et al. Extracellular and intracellular barriers in non-viral gene delivery. J Control Release 2003;93: 213-7.
27. Ruponen M, Hyvonen Z, Urtti A, et al. Nonviral gene delivery methods in cardiovascular diseases. Methods Mol Med 2005;108:315-28.
28. Melo LG, Pachori AS, Gnecchi M, et al. Genetic therapies for cardiovascular diseases. Trends Mol Med 2005;11:240-50.
29. Douglas JT. Adenoviral vectors for gene therapy. Mol Biotechnol 2007; 36:71-80.
30. Nemerow GR, Stewart PL. Role of alpha(v) integrins in adenovirus cell entry and gene delivery. Microbiol Mol Biol Rev 1999;63:725-34.
31. Koizumi N, Mizuguchi H, Sakurai F, et al. Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR- and alphav integrin-binding ablation. J Virol 2003;77: 13062-72.
32. Volpers C, Kochanek S. Adenoviral vectors for gene transfer and therapy. J Gene Med 2004;6(suppl 1):S164-71.
33. Boecker W, Bernecker OY, Wu JC, et al. Cardiac-specific gene expression facilitated by an enhanced myosin light chain promoter. Mol Imaging 2004;3:69-75.34.
34. del Monte F, Harding SE, Dec GW, et al. Targeting phospholamban by gene transfer in human heart failure. Circulation 2002;105:904-7.
35. del Monte F, Williams E, Lebeche D, et al. Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure. Circulation 2001;104: 1424-9.
36. Yla-Herttuala S. An update on angiogenic gene therapy: vascular endothelial growth factor and other directions. Curr Opin Mol Ther 2006;8: 295-300.
37. Yarborough M, Sharp RR. Public trust and research a decade later: what have we learned since Jesse Gelsinger's death? Mol Genet Metab 2009; 97:4-5.
38. Wilson JM. Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Mol Genet Metab 2009;96:151-7.
39. Nayak S, Herzog RW. Progress and prospects: immune responses to viral vectors. Gene Ther 2010;17:295-304.
40. Chirmule N, Propert K, Magosin S, et al. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 1999;6: 1574-83.
41. Jooss K, Chirmule N. Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy. Gene Ther 2003;10:955-63.
42. Yang Y, Nunes FA, Berencsi K, et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A 1994;91:4407-11.
43. Benihoud K, Yeh P, Perricaudet M. Adenovirus vectors for gene delivery. Curr Opin Biotechnol 1999;10:440-7.
44. Zoltick PW, Chirmule N, Schnell MA, et al. Biology of E1-deleted adenovirus vectors in nonhuman primate muscle. J Virol 2001;75: 5222-9.
45. Alba R, Bosch A, Chillon M. Gutless adenovirus: last-generation adenovirus for gene therapy. Gene Ther 2005;12(suppl 1):S18-27.
46. Xiong W, Goverdhana S, Sciascia SA, et al. Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses. J Virol 2006;80: 27-37.
47. Barcia C, Jimenez-Dalmaroni M, Kroeger KM, et al. One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications. Mol Ther 2007;15:2154-63.
48. Lowenstein PR, Mandel RJ, Xiong WD, et al. Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions. Curr Gene Ther 2007;7:347-60.
49. Weiss RA. How does HIV cause AIDS? Science 1993;260:1273-9.
50. Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM. Development of a self-inactivating lentivirus vector. J Virol 1998;72:8150-7.
51. Cronin J, Zhang XY, Reiser J. Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther 2005;5:387-98.
52. Peng KW, Pham L, Ye H, et al. Organ distribution of gene expression after intravenous infusion of targeted and untargeted lentiviral vectors. Gene Ther 2001;8:1456-63.
53. Kafri T, van Praag H, Ouyang L, et al. A packaging cell line for lentivirus vectors. J Virol 1999;73:576-84.
54. Marino MP, Luce MJ, Reiser J. Small- to large-scale production of lentivirus vectors. Methods Mol Biol 2003;229:43-55.
55. Pauwels K, Gijsbers R, Toelen J, et al. State-of-the-art lentiviral vectors for research use: risk assessment and biosafety recommendations. Curr Gene Ther 2009;9:459-74.
56. Bonci D, Cittadini A, Latronico MV, et al. 'Advanced' generation lentiviruses as efficient vectors for cardiomyocyte gene transduction in vitro and in vivo. Gene Ther 2003;10:630-6.
57. Nagata M, Takahashi M, Muramatsu S, et al. Efficient gene transfer of a simian immuno-deficiency viral vector into cardiomyocytes derived from primate embryonic stem cells. J Gene Med 2003;5:921-8.
58. Cao F, Lin S, Xie X, et al. In vivo visualization of embryonic stem cell survival, proliferation, and migration after cardiac delivery. Circulation 2006;113:1005-14.
59. Gallo P, Grimaldi S, Latronico MV, et al. A lentiviral vector with a short troponin-I promoter for tracking cardiomyocyte differentiation of human embryonic stem cells. Gene Ther 2008;15:161-70.
60. Kearns-Jonker M, Fischer-Lougheed J, Shulkin I, et al. Use of lentiviral vectors to induce long-term tolerance to gal(+) heart grafts. Transplantation 2004;77:1748-54.
61. Zhao J, Pettigrew GJ, Bolton EM, et al. Lentivirus-mediated gene transfer of viral interleukin-10 delays but does not prevent cardiac allograft rejection. Gene Ther 2005;12:1509-16.
62. Vassalli G, Simeoni E, Li JP, et al. Lentiviral gene transfer of the chemokine antagonist RANTES 9-68 prolongs heart graft survival. Transplantation 2006;81:240-6.
63. Fleury S, Simeoni E, Zuppinger C, et al. Multiply attenuated, self-inactivating lentiviral vectors efficiently deliver and express genes for extended periods of time in adult rat cardiomyocytes in vivo. Circulation 2003;107:2375-82.
64. Zhao J, Pettigrew GJ, Thomas J, et al. Lentiviral vectors for delivery of genes into neonatal and adult ventricular cardiac myocytes in vitro and in vivo. Basic Res Cardiol 2002;97:348-58.
65. Yoshimitsu M, Higuchi K, Dawood F, et al. Correction of cardiac abnormalities in fabry mice by direct intraventricular injection of a recombinant lentiviral vector that engineers expression of alpha-galactosidase A. Circ J 2006;70:1503-8.
66. Higuchi K, Ayach B, Sato T, et al. Direct injection of kit ligand-2 lentivirus improves cardiac repair and rescues mice post-myocardial infarction. Mol Ther 2009;17:262-8.
67. Niwano K, Arai M, Koitabashi N, et al. Lentiviral vector-mediated SERCA2 gene transfer protects against heart failure and left ventricular remodeling after myocardial infarction in rats. Mol Ther 2008; 16:1026-32.
68. Atchison RW, Casto BC, Hammon WM. Adenovirus-Associated Defective Virus Particles. Science 1965;149:754-6.
69. Hoggan MD, Blacklow NR, Rowe WP. Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics. Proc Natl Acad SciUSA1966;55:1467-74.
70. Blacklow NR, Hoggan MD, Kapikian AZ, et al. Epidemiology of adenovirus-associated virus infection in a nursery population. Am J Epidemiol 1968;88:368-78.
71. Carter BJ. Adeno-associated virus and the development of adeno-associated virus vectors: a historical perspective. Mol Ther 2004;10:981-9.
72. Fields BN, Knipe DM, Howley PM. Fields' virology. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2007.
73. Kerr JR. Parvoviruses. London; New York: Hodder Arnold; Distributed in the U.S.A. by Oxford University Press; 2006 74.
74. Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther 2006;14:316-27.
75. Gao G, Vandenberghe LH, Alvira MR, et al. Clades of Adeno-associated viruses are widely disseminated in human tissues. J Virol 2004;78: 6381-8.
76. Gao GP, Alvira MR, Wang L, et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A 2002;99:11854-9.
77. Schmidt M, Grot E, Cervenka P, et al. Identification and characterization of novel adeno-associated virus isolates in ATCC virus stocks. J Virol 2006;80:5082-5.
78. SchmidtM, Voutetakis A, Afione S, et al. Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J Virol 2008; 82:1399-406.
79. Lochrie MA, Tatsuno GP, Arbetman AE, et al. Adeno-associated virus (AAV) capsid genes isolated from rat and mouse liver genomic DNA define two new AAV species distantly related to AAV-5. Virology 2006; 353:68-82.
80. Mori S, Wang L, Takeuchi T, et al. Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein. Virology 2004;330:375-83.
81. Buning H, Perabo L, Coutelle O, et al. Recent developments in adenoassociated virus vector technology. J Gene Med 2008;10:717-33.
82. Michelfelder S, Trepel M. Adeno-associated viral vectors and their redirection to cell-type specific receptors. Adv Genet 2009;67:29-60.
83. Choi VW, McCarty DM, Samulski RJ. AAV hybrid serotypes: improved vectors for gene delivery. Curr Gene Ther 2005;5:299-310.
84. Hermonat PL, Muzyczka N. Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc Natl Acad Sci U S A 1984; 81:6466-70.
85. Rabinowitz JE, Rolling F, Li C, et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 2002;76:791-801.
86. Xiao X, Xiao W, Li J, et al. A novel 165-base-pair terminal repeat sequence is the sole cis requirement for the adeno-associated virus life cycle. J Virol 1997;71:941-8.
87. Samulski RJ, Berns KI, Tan M, et al. Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci U S A 1982;79:2077-81.
88. Ziello JE, Huang Y, Jovin IS. Cellular endocytosis and gene delivery. Mol Med 2010;16:222-9.
89. Duan D, Yue Y, Engelhardt JF. Consequences of DNA-dependent protein kinase catalytic subunit deficiency on recombinant adeno-associated virus genome circularization and heterodimerization in muscle tissue. J Virol 2003;77:4751-9.
90. Yang J, Zhou W, Zhang Y, et al. Concatamerization of adeno-associated virus circular genomes occurs through intermolecular recombination. J Virol 1999;73:9468-77.
91. Srivastava A. Adeno-associated virus-mediated gene transfer. J Cell Biochem 2008;105:17-24.
92. Jaski BE, Jessup ML, Mancini DM, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail 2009;15:171-81.
93. Jiang H, Pierce GF, Ozelo MC, et al. Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol Ther 2006;14:452-5.
94. Brantly ML, Chulay JD, Wang L, et al. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci U S A 2009;106:16363-8.
95. Maguire AM, High KA, Auricchio A, et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 doseescalation trial. Lancet 2009;374:1597-605.
96. Hadaczek P, Eberling JL, Pivirotto P, et al. Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. Mol Ther 2010;18:1458-61.
97. Niemeyer GP, Herzog RW, Mount J, et al. Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood 2009;113:797-806.
98. Di Pasquale G, Chiorini JA. AAV transcytosis through barrier epithelia and endothelium. Mol Ther 2006;13:506-16.
99. Van Vliet KM, Blouin V, Brument N, et al. The role of the adenoassociated virus capsid in gene transfer. Methods Mol Biol 2008;437: 51-91.
100. Akache B, Grimm D, Pandey K, et al. The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J Virol 2006;80:9831-6.
101. Kashiwakura Y, Tamayose K, Iwabuchi K, et al. Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection. J Virol 2005;79:609-14.
102. Qing K, Mah C, Hansen J, Zhou S, et al. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus. Nat Med 1999;5:71-7.
103. Kaludov N, Brown KE, Walters RW, et al. Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J Virol 2001;75:6884-93.
104. Summerford C, Bartlett JS, Samulski RJ. AlphaVbeta5 integrin: a coreceptor for adeno-associated virus type 2 infection. Nat Med 1999;5: 78-82.
105. Di Pasquale G, Davidson BL, Stein CS, et al. Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med 2003;9:1306-12.
106. Seiler MP, Miller AD, Zabner J, et al. Adeno-associated virus types 5 and 6 use distinct receptors for cell entry. Hum Gene Ther 2006;17:10-9.
107. Pacak CA, Mah CS, Thattaliyath BD, et al. Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res 2006;99:e3-9.
108. Zincarelli C, Soltys S, Rengo G, et al. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 2008;16:1073-80.
109. Wang B, Li J, Fu FH, et al. Systemic human minidystrophin gene transfer improves functions and life span of dystrophin and dystrophin/utrophin-deficient mice. J Orthop Res 2009;27:421-6.
110. Bish LT, Morine K, Sleeper MM, et al. Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum Gene Ther 2008; 19:1359-68.
111. Prasad KM, Xu Y, Yang Z, et al. Robust cardiomyocyte-specific gene expression following systemic injection of AAV: in vivo gene delivery follows a Poisson distribution. Gene Ther 2011;18:43-52.
112. Wang Z, Zhu T, Qiao C, et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol 2005;23: 321-8.
113. Palomeque J, Chemaly ER, Colosi P, et al. Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo. Gene Ther 2007; 14:989-97.
114. Muller OJ, Schinkel S, Kleinschmidt JA, et al. Augmentation of AAVmediated cardiac gene transfer after systemic administration in adult rats. Gene Ther 2008;15:1558-65.
115. Yue Y, Ghosh A, Long C, et al. A single intravenous injection of adenoassociated virus serotype-9 leads to whole body skeletal muscle transduction in dogs. Mol Ther 2008;16:1944-52.
116. Blankinship MJ, Gregorevic P, Allen JM, et al. Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6. Mol Ther 2004;10:671-8.
117. Gregorevic P, Schultz BR, Allen JM, et al. Evaluation of vascular delivery methodologies to enhance rAAV6-mediated gene transfer to canine striated musculature. Mol Ther 2009;17:1427-33.
118. Hadri L, Bobe R, Kawase Y, et al. SERCA2a gene transfer enhances eNOS expression and activity in endothelial cells. Mol Ther 2010;18: 1284-92.
119. Kawase Y, Ly HQ, Prunier F, et al. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol 2008;51:1112-9.
120. Su H, Yeghiazarians Y, Lee A, et al. AAV serotype 1 mediates more efficient gene transfer to pig myocardium than AAV serotype 2 and plasmid. J Gene Med 2008;10:33-41.
121. Raake PW, Hinkel R, Muller S, et al. Cardio-specific long-term gene expression in a porcine model after selective pressure-regulated retroinfusion of adeno-associated viral (AAV) vectors. Gene Ther 2008;15: 12-7.
122. Wu JC, Spin JM, Cao F, et al. Transcriptional profiling of reporter genes used for molecular imaging of embryonic stem cell transplantation. Physiol Genomics 2006;25:29-38.
123. Asokan A, Conway JC, Phillips JL, et al. Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nat Biotechnol 2010;28:79-82.
124. Gray SJ, Blake BL, Criswell HE, et al. Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Mol Ther 2010;18:570-8.
125. Koerber JT, Jang JH, Schaffer DV. DNA shuffling of adeno-associated virus yields functionally diverse viral progeny. Mol Ther 2008;16: 1703-9.
126. Li W, Asokan A, Wu Z, et al. Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol Ther 2008;16:1252-60.
127. Ying Y, Muller OJ, Goehringer C, et al. Heart-targeted adeno-associated viral vectors selected by in vivo biopanning of a random viral display peptide library. Gene Ther 2010;17:980-90.
128. Franz WM, Rothmann T, Frey N, et al. Analysis of tissue-specific gene delivery by recombinant adenoviruses containing cardiac-specific promoters. Cardiovasc Res 1997;35:560-6.
129. Phillips MI, Tang Y, Schmidt-Ott K, et al. Vigilant vector: heart-specific promoter in an adeno-associated virus vector for cardioprotection. Hypertension 2002;39:651-5.
130. Su H, Huang Y, Takagawa J, et al. AAV serotype-1 mediates early onset of gene expression in mouse hearts and results in better therapeutic effect. Gene Ther 2006;13:1495-502.
131. Pacak CA, Sakai Y, Thattaliyath BD, et al. Tissue specific promoters improve specificity of AAV9 mediated transgene expression following intra-vascular gene delivery in neonatal mice. Genet Vaccines Ther 2008;6:13.
132. Salva MZ, Himeda CL, Tai PW, et al. Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle. Mol Ther 2007;15:320-9.
133. Kelly EJ, Russell SJ. MicroRNAs and the regulation of vector tropism. Mol Ther 2009;17:409-16.
134. Suzuki T, Sakurai F, Nakamura S, et al. miR-122a-regulated expression of a suicide gene prevents hepatotoxicity without altering antitumor effects in suicide gene therapy. Mol Ther 2008;16:1719-26.
135. Duan D, Yue Y, Engelhardt JF. Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison. Mol Ther 2001;4:383-91.
136. Lai Y, Li D, Yue Y, et al. Design of trans-splicing adeno-associated viral vectors for Duchenne muscular dystrophy gene therapy. Methods Mol Biol 2008;433:259-75.
137. Lai Y, Yue Y, Liu M, et al. Efficient in vivo gene expression by transsplicing adeno-associated viral vectors. Nat Biotechnol 2005;23:1435-9.
138. Sun L, Li J, Xiao X. Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization. Nat Med 2000;6:599-602.
139. Champion HC, Georgakopoulos D, Haldar S, et al. Robust adenoviral and adeno-associated viral gene transfer to the in vivo murine heart: application to study of phospholamban physiology. Circulation 2003; 108:2790-7.
140. McCarty DM. Self-complementary AAV vectors; advances and applications. Mol Ther 2008;16:1648-56.
141. McCarty DM, Young SM Jr, Samulski RJ. Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet 2004; 38:819-845.
142. Inagaki K, Ma C, Storm TA, et al. The role of DNA-PKcs and artemis in opening viral DNA hairpin termini in various tissues in mice. J Virol 2007;81:11304-21.
143. Donsante A, Miller DG, Li Y, et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science 2007;317:477.
144. Bell P, Moscioni AD, McCarter RJ, et al. Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver. Mol Ther 2006;14:34-44.
145. Bell P, Wang L, Lebherz C, et al. No evidence for tumorigenesis of AAV vectors in a large-scale study in mice. Mol Ther 2005;12:299-306.
146. Calcedo R, Vandenberghe LH, Gao G, et al. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis 2009; 199:381-90.
147. Madsen D, Cantwell ER, O'Brien T, et al. Adeno-associated virus serotype 2 induces cell-mediated immune responses directed against multiple epitopes of the capsid protein VP1. J Gen Virol 2009;90:2622-33.
148. Boutin S, Monteilhet V, Veron P, et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther 2010;21:704-12.
149. Hasbrouck NC, High KA. AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects. Gene Ther 2008;15: 870-5.
150. Mingozzi F, High KA. Immune responses to AAV in clinical trials. Curr Gene Ther 2007;7:316-24.
151. Mingozzi F, Maus MV, Hui DJ, et al. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med 2007;13:419-22.
152. Breous E, Somanathan S, Wilson JM. BALB/c mice show impaired hepatic tolerogenic response following AAV gene transfer to the liver. Mol Ther 2010;18:766-74.
153. Mays LE, Vandenberghe LH, Xiao R, et al. Adeno-associated virus capsid structure drives CD4-dependent CD8+ T cell response to vector encoded proteins. J Immunol 2009;182:6051-60.
154. Li C, Hirsch M, Asokan A, et al. Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo. J Virol 2007;81: 7540-7.
155. Somanathan S, Breous E, Bell P, et al. AAV vectors avoid inflammatory signals necessary to render transduced hepatocyte targets for destructive T cells. Mol Ther 2010;18:977-82.
156. Herzog RW. Immune responses to AAV capsid: are mice not humans after all? Mol Ther 2007;15:649-50.
157. Zaiss AK, Muruve DA. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge. Gene Ther 2008;15: 808-16.
158. Arruda VR, Favaro P, Finn JD. Strategies to modulate immune responses: a new frontier for gene therapy. Mol Ther 2009;17:1492-503.
159. Vandenberghe LH, Wilson JM, Gao G. Tailoring the AAV vector capsid for gene therapy. Gene Ther 2009;16:311-9.
160. Sack BK, Herzog RW. Evading the immune response upon in vivo gene therapy with viral vectors. Curr Opin Mol Ther 2009;11:493-503.
161. Roth DM, Lai NC, Gao MH, et al. Nitroprusside increases gene transfer associated with intracoronary delivery of adenovirus. Hum Gene Ther 2004;15:989-94.
162. Yang L, Jiang J, Drouin LM, et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl Acad Sci U S A 2009;106:3946-51.
163. French BA, Mazur W, Geske RS, et al. Direct in vivo gene transfer into porcine myocardium using replication-deficient adenoviral vectors. Circulation 1994;90:2414-24.
164. Grossman PM, Han Z, Palasis M, et al. Incomplete retention after direct myocardial injection. Catheter Cardiovasc Interv 2002;55:392-7.
165. Schwarz ER, Speakman MT, Patterson M, et al. Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat-angiogenesis and angioma formation. J Am Coll Cardiol 2000;35:1323-30.
166. Wright MJ, Wightman LM, Latchman DS, et al. In vivo myocardial gene transfer: optimization and evaluation of intracoronary gene delivery in vivo. Gene Ther 2001;8:1833-9.
167. Bish LT, Sleeper MM, Brainard B, et al. Percutaneous transendocardial delivery of self-complementary adeno-associated virus 6 achieves global cardiac gene transfer in canines. Mol Ther 2008;16:1953-9.
168. Laham RJ, Post M, Rezaee M, et al. Transendocardial and transepicardial intramyocardial fibroblast growth factor-2 administration: myocardial and tissue distribution. Drug Metab Dispos 2005;33:1101-7.
169. Kornowski R, Leon MB, Fuchs S, et al. Electromagnetic guidance for catheter-based transendocardial injection: a platform for intramyocardial angiogenesis therapy. Results in normal and ischemic porcine models. J Am Coll Cardiol 2000;35:1031-9.
170. O'Donnell JM, Lewandowski ED. Efficient, cardiac-specific adenoviral gene transfer in rat heart by isolated retrograde perfusion in vivo. Gene Ther 2005;12:958-64.
171. Ohshima S, Shin JH, Yuasa K, et al. Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle. Mol Ther 2009;17:73-80.
172. Grines CL, Watkins MW, Helmer G, et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002; 105:1291-7.
173. Gyongyosi M, Khorsand A, Zamini S, et al. NOGA-guided analysis of regional myocardial perfusion abnormalities treated with intramyocardial injections of plasmid encoding vascular endothelial growth factor A-165 in patients with chronic myocardial ischemia: subanalysis of the EUROINJECT-ONE multicenter double-blind randomized study. Circulation 2005;112:I157-65.
174. Losordo DW, Vale PR, Symes JF, et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998; 98:2800-4.
175. Lamping KG, Rios CD, Chun JA, et al. Intrapericardial administration of adenovirus for gene transfer. Am J Physiol 1997;272:H310-7.
176. March KL, Woody M, Mehdi K, et al. Efficient in vivo catheter-based pericardial gene transfer mediated by adenoviral vectors. Clin Cardiol 1999;22:I23-9.
177. Fromes Y, Salmon A, Wang X, et al. Gene delivery to the myocardium by intrapericardial injection. Gene Ther 1999;6:683-8.
178. Donahue JK, Heldman AW, Fraser H, et al. Focal modification of electrical conduction in the heart by viral gene transfer. Nat Med 2000;6: 1395-8.
179. Muller OJ, Katus HA, Bekeredjian R. Targeting the heart with gene therapy-optimized gene delivery methods. Cardiovasc Res 2007;73: 453-62.
180. Hajjar RJ, Schmidt U, Matsui T, et al. Modulation of ventricular function through gene transfer in vivo. Proc Natl Acad Sci U S A 1998;95: 5251-56.
181. Hayase M, Del Monte F, Kawase Y, et al. Catheter-based antegrade intracoronary viral gene delivery with coronary venous blockade. Am J Physiol Heart Circ Physiol 2005;288:H2995-3000.
182. Ikeda Y, Gu Y, Iwanaga Y, et al. Restoration of deficient membrane proteins in the cardiomyopathic hamster by in vivo cardiac gene transfer. Circulation 2002;105:502-8.
183. Bridges CR, Gopal K, Holt DE, et al. Efficient myocyte gene delivery with complete cardiac surgical isolation in situ. J Thorac Cardiovasc Surg 2005;130:1364.
184. Davidson MJ, Jones JM, Emani SM, et al. Cardiac gene delivery with cardiopulmonary bypass. Circulation 2001;104:131-3.
185. Jones JM, Wilson KH, Koch WJ, et al. Adenoviral gene transfer to the heart during cardiopulmonary bypass: effect of myocardial protection technique on transgene expression. Eur J Cardiothorac Surg 2002;21: 847-52.
186. Jones JM, Petrofski JA, Wilson KH, et al. Beta2 adrenoceptor gene therapy ameliorates left ventricular dysfunction following cardiac surgery. Eur J Cardiothorac Surg 2004;26:1161-8.
187. Raake P, von Degenfeld G, Hinkel R, et al. Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins: comparison with surgical and percutaneous intramyocardial gene delivery. J Am Coll Cardiol 2004;44:1124-9.
188. Boekstegers P, von Degenfeld G, Giehrl W, et al. Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins. Gene Ther 2000;7:232-40.
189. Logeart D, Hatem SN, Heimburger M, et al. How to optimize in vivo gene transfer to cardiac myocytes: mechanical or pharmacological procedures? Hum Gene Ther 2001;12:1601-10.
190. Logeart D, Vinet L, Ragot T, et al. Percutaneous intracoronary delivery of SERCA gene increases myocardial function: a tissue Doppler imaging echocardiographic study. Am J Physiol Heart Circ Physiol 2006;291: H1773-9.
191. Emani SM, Shah AS, Bowman MK, et al. Catheter-based intracoronary myocardial adenoviral gene delivery: importance of intraluminal seal and infusion flow rate. Mol Ther 2003;8:306-13.
192. Hajjar RJ, Zsebo K, Deckelbaum L, et al. Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J Card Fail 2008;14:355-67.
193. Beeri R, Guerrero JL, Supple G, et al. New efficient catheter-based system for myocardial gene delivery. Circulation 2002;106:1756-9.
194. Donahue JK. Gene therapy, angiogenesis, Sonic Hedgehog: Sonic the Hedgehog to the rescue? Gene Ther 2006;13:998-9.
195. Donahue JK, Kikkawa K, Thomas AD, et al. Acceleration of widespread adenoviral gene transfer to intact rabbit hearts by coronary perfusion with low calcium and serotonin. Gene Ther 1998;5:630-4.
196. Wu HM, Huang Q, Yuan Y, et al. VEGF induces NO-dependent hyperpermeability in coronary venules. Am J Physiol 1996;271:H2735-9.
197. Roth DM, Lai NC, Gao MH, et al. Indirect intracoronary delivery of adenovirus encoding adenylyl cyclase increases left ventricular contractile function in mice. Am J Physiol Heart Circ Physiol 2004; 287:H172-7.
198. Gupta R, Tongers J, Losordo DW. Human studies of angiogenic gene therapy. Circ Res 2009;105:724-36.
199. Ribatti D. The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis: a historical review. Br J Haematol 2005;128:303-9.
200. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996;380:435-9.
201. Ferrara N, Bunting S. Vascular endothelial growth factor, a specific regulator of angiogenesis. Curr Opin Nephrol Hypertens 1996;5:35-44.
202. Zachary I, Morgan R. Therapeutic angiogenesis for cardiovascular disease: biological context, challenges, prospects. Heart 2011; 97:181-9.
203. Khurana R, Simons M, Martin JF, et al. Role of angiogenesis in cardiovascular disease: a critical appraisal. Circulation 2005;112:1813-24.
204. Atluri P, Woo YJ. Pro-angiogenic cytokines as cardiovascular therapeutics: assessing the potential. BioDrugs 2008;22:209-22.
205. Hedman M, Hartikainen J, Syvanne M, et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003;107:2677-83.
206. Laitinen M, Hartikainen J, Hiltunen MO, et al. Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty. Hum Gene Ther 2000;11:263-70.
207. Hedman M, Muona K, Hedman A, et al. Eight-year safety follow-up of coronary artery disease patients after local intracoronary VEGF gene transfer. Gene Ther 2009;16:629-34.
208. Stewart DJ, Hilton JD, Arnold JM, et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther 2006;13:1503-11.
209. Stewart DJ, Kutryk MJ, Fitchett D, et al. VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial. Mol Ther 2009;17: 1109-15.
210. Mayhan WG. VEGF increases permeability of the blood-brain barrier via a nitric oxide synthase/cGMP-dependent pathway. Am J Physiol 1999;276:C1148-53.
211. Rajagopalan S, Mohler ER 3rd, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003;108:1933-8.
212. Murakami M, Simons M. Fibroblast growth factor regulation of neovascularization. Curr Opin Hematol 2008;15:215-20.
213. Aviles RJ, Annex BH, Lederman RJ. Testing clinical therapeutic angiogenesis using basic fibroblast growth factor (FGF-2). Br J Pharmacol 2003;140:637-46.
214. Henry TD, Grines CL, Watkins MW, et al. Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J Am Coll Cardiol 2007;50:1038-46.
215. Kapur NK, Rade JJ. Fibroblast growth factor 4 gene therapy for chronic ischemic heart disease. Trends Cardiovasc Med 2008;18:133-41.
216. Nikol S, Baumgartner I, Van Belle E, et al. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther 2008;16:972-8.
217. Morishita R, Aoki M, Hashiya N, et al. Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension 2004;44:203-9.
218. del Monte F, Harding SE, Schmidt U, et al. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation 1999;100:2308-11.
219. Lipskaia L, Pinet C, Fromes Y, et al. Mutation of delta-sarcoglycan is associated with Ca(2+)-dependent vascular remodeling in the Syrian hamster. Am J Pathol 2007;171:162-71.
220. Vandebrouck A, Ducret T, Basset O, et al. Regulation of store-operated calcium entries and mitochondrial uptake by minidystrophin expression in cultured myotubes. FASEB J 2006;20:136-8.
221. Kawase Y, Hajjar RJ. The cardiac sarcoplasmic/endoplasmic reticulum calcium ATPase: a potent target for cardiovascular diseases. Nat Clin Pract Cardiovasc Med 2008;5:554-65.
222. Venetucci LA, Trafford AW, O'Neill SC, et al. The sarcoplasmic reticulum and arrhythmogenic calcium release. Cardiovasc Res 2008; 77:285-92.
223. Keller M, Kao JP, Egger M, et al. Calcium waves driven by "sensitization" wave-fronts. Cardiovasc Res 2007;74:39-45.
224. Davia K, Bernobich E, Ranu HK, et al. SERCA2A overexpression decreases the incidence of aftercontractions in adult rabbit ventricular myocytes. J Mol Cell Cardiol 2001;33:1005-15.
225. Nakayama H, Otsu K, Yamaguchi O, et al. Cardiac-specific overexpression of a high Ca2+ affinity mutant of SERCA2a attenuates in vivo pressure overload cardiac hypertrophy. FASEB J 2003;17:61-3.
226. Sakata S, Lebeche D, Sakata Y, et al. Transcoronary gene transfer of SERCA2a increases coronary blood flow and decreases cardiomyocyte size in a type 2 diabetic rat model. Am J Physiol Heart Circ Physiol 2007;292:H1204-7.
227. Lipskaia L, del Monte F, Capiod T, et al. Sarco/endoplasmic reticulum Ca2+-ATPase gene transfer reduces vascular smooth muscle cell proliferation and neointima formation in the rat. Circ Res 2005;97:488-95.
228. Pleger ST, Harris DM, Shan C, et al. Endothelial S100A1 modulates vascular function via nitric oxide. Circ Res 2008;102:786-94.
229. Hadri L, Lipskaia L, Kawase Y, et al. Transcoronary gene transfer of SERCA2a increases coronary blood flow trought an increase of eNOS activity in endothelial cells.. Circ Res 2007;101:E65.
230. Kaye DM, Preovolos A, Marshall T, et al. Percutaneous cardiac recirculation-mediated gene transfer of an inhibitory phospholamban peptide reverses advanced heart failure in large animals. J Am Coll Cardiol 2007; 50:253-60.
231. Suckau L, Fechner H, Chemaly E, et al. Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation 2009; 119:1241-52.
232. Nicolaou P, Hajjar RJ, Kranias EG. Role of protein phosphatase-1 inhibitor-1 in cardiac physiology and pathophysiology. J Mol Cell Cardiol 2009;47:365-71.
233. Pathak A, del Monte F, Zhao W, et al. Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1. Circ Res 2005;96:756-6.
234. Nicolaou P, Rodriguez P, Ren X, et al. Inducible expression of active protein phosphatase-1 inhibitor-1 enhances basal cardiac function and protects against ischemia/reperfusion injury. Circ Res 2009;104: 1012-20.
235. Pathak A, Baldwin B, Kranias EG. Key protein alterations associated with hyperdynamic cardiac function: insights based on proteomic analysis of the protein phosphatase 1 inhibitor-1 overexpressing hearts. Hellenic J Cardiol 2007;48:30-6.
236. Du XJ, Cole TJ, Tenis N, et al. Impaired cardiac contractility response to hemodynamic stress in S100A1-deficient mice. Mol Cell Biol 2002;22: 2821-9.
237. Pleger ST, Most P, Boucher M, et al. Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue. Circulation 2007;115:2506-15.
238. Pleger ST, Boucher M, Most P, et al. Targeting myocardial beta-adrenergic receptor signaling and calcium cycling for heart failure gene therapy. J Card Fail 2007;13:401-14.
239. El-Armouche A, Eschenhagen T. Beta-adrenergic stimulation and myocardial function in the failing heart. Heart Fail Rev 2009;14:225-41.
240. Sucharov CC. Beta-adrenergic pathways in human heart failure. Expert Rev Cardiovasc Ther 2007;5:119-24.
241. Brodde OE, Bruck H, Leineweber K. Cardiac adrenoceptors: physiological and pathophysiological relevance. J Pharmacol Sci 2006;100:323-7.
242. Gorre F, Vandekerckhove H. Beta-blockers: focus on mechanism of action. Which beta-blocker, when and why? Acta Cardiol 2010;65: 565-70.
243. Satwani S, Dec GW, Narula J. Beta-adrenergic blockers in heart failure: review of mechanisms of action and clinical outcomes. J Cardiovasc Pharmacol Ther 2004;9:243-55.
244. Du XJ, Autelitano DJ, Dilley RJ, et al. beta(2)-adrenergic receptor overexpression exacerbates development of heart failure after aortic stenosis. Circulation 2000;101:71-7.
245. Milano CA, Allen LF, Rockman HA, et al. Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. Science 1994;264:582-6.
246. Shah AS, White DC, Tai O, et al. Adenovirus-mediated genetic manipulation of the myocardial beta-adrenergic signaling system in transplanted hearts. J Thorac Cardiovasc Surg 2000;120:581-8.
247. Dorn GW 2nd, Tepe NM, Lorenz JN, et al. Low- and high-level transgenic expression of beta2-adrenergic receptors differentially affect cardiac hypertrophy and function in Galphaq-overexpressing mice. Proc Natl Acad Sci U S A 1999;96:6400-5.
248. Lee S, Schwinger RH, Brixius K. Genetically changed mice with chronic deficiency or overexpression of the beta-adrenoceptors-what can we learn for the therapy of heart failure? Pflugers Arch 2008;455:767-4.
249. Liggett SB. Pharmacogenetics of beta-1- and beta-2-adrenergic receptors. Pharmacology 2000;61:167-73.
250. Dorn GW 2nd. GRK mythology: G-protein receptor kinases in cardiovascular disease. J Mol Med 2009;87:455-63.
251. Penela P, Murga C, Ribas C, et al. The complex G protein-coupled receptor kinase 2 (GRK2) interactome unveils new physiopathological targets. Br J Pharmacol 2010;160:821-32.
252. Dzimiri N, Muiya P, Andres E, et al. Differential functional expression of human myocardial G protein receptor kinases in left ventricular cardiac diseases. Eur J Pharmacol 2004;489:167-77.
253. Leineweber K, Rohe P, Beilfuss A, et al. G-protein-coupled receptor kinase activity in human heart failure: effects of beta-adrenoceptor blockade. Cardiovasc Res 2005;66:512-9.
254. Penela P, Murga C, Ribas C, et al. Mechanisms of regulation of G protein-coupled receptor kinases (GRKs) and cardiovascular disease. Cardiovasc Res 2006;69:46-56.
255. El-Armouche A, Zolk O, Rau T, et al. Inhibitory G-proteins and their role in desensitization of the adenylyl cyclase pathway in heart failure. Cardiovasc Res 2003;60:478-87.
256. Phan HM, Gao MH, Lai NC, et al. New signaling pathways associated with increased cardiac adenylyl cyclase 6 expression: implications for possible congestive heart failure therapy. Trends Cardiovasc Med 2007; 17:215-21.
257. Vatner SF, Yan L, Ishikawa Y, et al. Adenylyl cyclase type 5 disruption prolongs longevity and protects the heart against stress. Circ J 2009;73: 195-200.
258. Hammond HK. Adenylyl cyclase gene transfer in heart failure. Ann N Y Acad Sci 2006;1080:426-36.
259. Ahuja P, Sdek P, MacLellan WR. Cardiac myocyte cell cycle control in development, disease, and regeneration. Physiol Rev 2007;87:521-44.
260. Stamm C, Choi YH, Nasseri B, et al. A heart full of stem cells: the spectrum of myocardial progenitor cells in the postnatal heart. Ther Adv Cardiovasc Dis 2009;3:215-29.
261. Costa AD. Divide to survive: myocardial regeneration and functional recovery after cell cycle activation in injured hearts. Cardiovasc Res 2008; 78:1-2.
262. Busk PK, Hinrichsen R, Bartkova J, et al. Cyclin D2 induces proliferation of cardiac myocytes and represses hypertrophy. Exp Cell Res 2005; 304:149-61.
263. Cheng RK, Asai T, Tang H, et al. Cyclin A2 induces cardiac regeneration after myocardial infarction and prevents heart failure. Circ Res 2007; 100:1741-8.
264. Hassink RJ, Pasumarthi KB, Nakajima H, et al. Cardiomyocyte cell cycle activation improves cardiac function after myocardial infarction. Cardiovasc Res 2008;78:18-25.
265. Pasumarthi KB, Nakajima H, Nakajima HO, et al. Targeted expression of cyclin D2 results in cardiomyocyte DNA synthesis and infarct regression in transgenic mice. Circ Res 2005;96:110-8.
266. Woo YJ, Panlilio CM, Cheng RK, et al. Therapeutic delivery of cyclin A2 induces myocardial regeneration and enhances cardiac function in ischemic heart failure. Circulation 2006;114:I206-13.
267. Zhu W, Hassink RJ, Rubart M, et al. Cell-cycle-based strategies to drive myocardial repair. Pediatr Cardiol 2009;30:710-15.
268. Yasmeen A, Berdel WE, Serve H, et al. E- and A-type cyclins as markers for cancer diagnosis and prognosis. Expert Rev Mol Diagn 2003;3:617-33.
269. Pouly J, Bruneval P, Mandet C, et al. Cardiac stem cells in the real world. J Thorac Cardiovasc Surg 2008;135:673-8.
270. Pittenger MF, Martin BJ. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res 2004;95:9-20.
271. Choi YH, Kurtz A, Stamm C. Mesenchymal stem cells for cardiac cell therapy. Hum Gene Ther 2011;22:3-17.
272. Mangi AA, Noiseux N, Kong D, et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 2003;9:1195-201.
273. Yu YS, Shen ZY, Ye WX, et al. AKT-modified autologous intracoronary mesenchymal stem cells prevent remodeling and repair in swine infarcted myocardium. Chin Med J (Engl) 2010;123:1702-8.
274. Fan L, Lin C, Zhuo S, et al. Transplantation with survivin-engineered mesenchymal stem cells results in better prognosis in a rat model of myocardial infarction. Eur J Heart Fail 2009;11:1023-30.
275. Li W, Ma N, Ong LL, et al. Bcl-2 engineered MSCs inhibited apoptosis and improved heart function. Stem Cells 2007;25:2118-27.
276. Cheng Z, Ou L, Zhou X, et al. Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol Ther 2008;16:571-9.
277. Tang J, Wang J, Yang J, et al. Mesenchymal stem cells over-expressing SDF-1 promote angiogenesis and improve heart function in experimental myocardial infarction in rats. Eur J Cardiothorac Surg 2009; 36:644-50.
278. Gao F, He T, Wang H, et al. A promising strategy for the treatment of ischemic heart disease: mesenchymal stem cell-mediated vascular endothelial growth factor gene transfer in rats. Can J Cardiol 2007; 23:891-8.
279. Tang J, Wang J, Kong X, et al. Vascular endothelial growth factor promotes cardiac stem cell migration via the PI3K/Akt pathway. Exp Cell Res 2009;315:3521-31.
280. Tang J, Wang J, Zheng F, et al. Combination of chemokine and angiogenic factor genes and mesenchymal stem cells could enhance angiogenesis and improve cardiac function after acute myocardial infarction in rats. Mol Cell Biochem 2010;339:107-18.
281. Chiriac A, Nelson TJ, Faustino RS, et al. Cardiogenic induction of pluripotent stem cells streamlined through a conserved SDF-1/VEGF/ BMP2 integrated network. PLoS One 2010;5:e9943.
282. Chiriac A, Terzic A, Park S, et al. SDF-1-enhanced cardiogenesis requires CXCR4 induction in pluripotent stem cells. J Cardiovasc Transl Res 2010;3:674-82.
283. Tang J, Wang J, Yang J, et al. Adenovirus-mediated stromal cell-derivedfactor-1alpha gene transfer induces cardiac preservation after infarction via angiogenesis of CD133+stem cells and anti-apoptosis. Interact Cardiovasc Thorac Surg 2008;7:767-70.
284. Juventas Therapeutics Inc.Study to evaluate the safety of a single escalating dose of ACRX-100 in adults with ischemic heart failure. Available at: http://clinicaltrials.gov/show/NCT01082094. Accessed February 5, 2011.
285. Shim W, Mehta A, Lim SY, et al. G-CSF for stem cell therapy in acute myocardial infarction: friend or foe? Cardiovasc Res 2011;89:20-30.
286. Fujii H, Li SH, Wu J, et al. Repeated and targeted transfer of angiogenic plasmids into the infarcted rat heart via ultrasound targeted microbubble destruction enhances cardiac repair. Eur Heart J 2011. [Epub ahead of print]
287. Nelson TJ, Martinez-Fernandez A, Terzic A. Induced pluripotent stem cells: developmental biology to regenerative medicine. Nat Rev Cardiol 2010;7:700-10.
288. Nelson TJ, Martinez-Fernandez A, Yamada S, et al. Induced pluripotent stem cells: advances to applications. Stem Cells Cloning 2010;3:29-37.
289. Galende E, Karakikes I, Edelmann L, et al. Amniotic fluid cells are more efficiently reprogrammed to pluripotency than adult cells. Cell Reprogram 2010;12:117-25.
290. Kunisato A, Wakatsuki M, Kodama Y, et al. Generation of induced pluripotent stem cells by efficient reprogramming of adult bone marrow cells. Stem Cells Dev 2010;19:229-38.
291. Martinez-Fernandez A, Nelson TJ, Yamada S, et al. iPS programmed without c-MYC yield proficient cardiogenesis for functional heart chimerism. Circ Res 2009;105:648-56.
292. Nelson TJ, Martinez-Fernandez A, Yamada S, et al. Induced pluripotent reprogramming from promiscuous human stemness related factors. Clin Transl Sci 2009;2:118-26.
293. Yoshida Y, Yamanaka S. iPS cells: A source of cardiac regeneration. J Mol Cell Cardiol 2011;50:327-32.
294. KH Hammond. AC6 gene transfer for congestive heart failure. Available at: http://clinicaltrials.gov/show/NCT00787059. Accessed February 5, 2011.